Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B001 in recurrent/metastatic head and neck squamous cell carcinoma
NCT05044897Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab in head and neck squamous cell carcinoma (HNSCC), sponsored by Biokin Pharmaceutical. Started Oct 2021; status: active, not recruiting.
02
Drugs
izalontamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05044897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044897.